Boston Scientific Corporation (BSX), 2024 Q4 earnings digest

$BSX has just announced its Q4 2024 earnings, showcasing a solid operational sales growth of 23% and organic sales growth of 20%, exceeding previous guidance. 📈 Key highlights include an adjusted EPS of $0.70, reflecting a 26% increase year-over-year. Notably, the company is forecasting 2025 organic growth of 10-12%, amid potential foreign exchange headwinds and competitive pressures. ⚖️ With strong demand for innovations like FerraPulse and synergistic acquisitions on the horizon, future opportunities appear promising. For more details, visit valueverge.com/BSX.